Editas Receives Australian Regulatory Approval for SCOPE Phase 1/2 Trial
Editas Medicine secured regulatory approval for the Phase 1/2 Strive study of EDIT-401 in Australia and presented preclinical data showing durable effects. The company's cash runway extends into the second half of 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed